1. Upfront autologous stem cell transplantation for untreated diffuse large B cell lymphoma patients in rituximab era: a systematic review and meta-analysis
   Shu-Yun Ma et al, 2020, Annals of Hematology CrossRef
2. Short- and long-term outcomes from the upfront high-dose chemotherapy, followed by autologous hematopoietic stem cell transplantation in diffuse large B-cell lymphoma
   A. K. Koviazin et al, 2022, Meditsinskiy sovet = Medical Council CrossRef
3. Beta2-microglobulin is a valuable marker and identifies a poor-prognosis subgroup among intermediate-risk patients with diffuse large B cell lymphoma
   Ning-Chun Chen et al, 2023, Clinical and Experimental Medicine CrossRef
4. Outcomes of high dose therapy and autologous haematopoietic stem cell transplantation for non‐hodgkin lymphoma: A retrospective analysis in a resource‐limited country
   Nur Adila Anuar et al, 2021, International Journal of Clinical Practice CrossRef
5. The significance of upfront autologous stem cell transplantation for high‐intermediate/high‐risk stage IV diffuse large B‐cell lymphoma
   Aleksei K. Koviazin et al, 2023, Cancer Reports CrossRef
6. CAR T-Cell Persistence Correlates with Improved Outcome in Patients with B-Cell Lymphoma
   Valerie Wittibschlager et al, 2023, International Journal of Molecular Sciences CrossRef